Business Summary
China Pharma Holdings, Inc. is a Nevada-incorporated holding company that operates entirely through its wholly owned PRC subsidiary, Hainan Helpson Medical and Biotechnology Co., Ltd. ("Helpson"), based in Haikou, Hainan Province. Through Helpson, the company develops, manufactures, and markets pharmaceutical products for human use in the PRC, primarily targeting high-incidence and high-mortality diseases including cardiovascular, CNS, infectious, and digestive conditions. Revenue is generated through product sales of NMPA-approved prescription drugs distributed via provincially licensed pharmaceutical logistics companies to hospitals and OTC pharmacies.
Products & Services
Pharmaceutical Products (19 approved, prescription-based):
- CNS & Cerebrovascular (7 products): Cerebroprotein Hydrolysate Injection, Gastrodin Injection, Propylgallate for Injection, Ozagrel Sodium for Injection, Alginic Sodium Diester Injection, Bumetanide for Injection, Candesartan (hypertension; passed consistency evaluation August 2023)
- Anti-Infection & Respiratory (6 products): Roxithromycin Dispersible Tablets, Cefaclor Dispersible Tablets, Cefalexin Capsules, Andrographolide, Clarithromycin Granules and Capsules, Naproxen Sodium/Pseudophedrine Sustained Release Tablet...
AI-generated summary of Item 1 (Business) from the 10-K filed Mar 31, 2025 — View filing on SEC.gov. May contain errors — refer to the filing for authoritative information.
Across SEC filings
Institutional holders · 13F
Q3 2026| Largest holders | Reported value |
|---|---|
| SABBY MANAGEMENT LLC | $202.6K |
| JANE STREET GROUP LLC | $23.3K |
| Virtu Financial LLC | $16.0K |
| StoneX Group Inc | $13.6K |
| XTX Topco Ltd | $8.2K |
Annual results · 10-K
Fiscal 2025- Revenue
- $4.1M
- Net loss
- -$3.2M
As reported in the fiscal 2025 annual report.
Securities
| CUSIP | Security | Type |
|---|---|---|
| 16941T401 | CPHI CHINA PHARMA HOLDINGS INC | Common stock |